

TITLE PAGE

*For prepublication deposit in medRxiv*

## **Dopamine D<sub>1</sub> agonist effects in late-stage Parkinson's disease**

Mechelle M. Lewis, Ph.D.<sup>\*, a,b,i</sup>, Lauren Jodi Van Scoy<sup>\*, M.D., c,d</sup>, Richard B. Mailman<sup>\*, Ph.D., a,b,i</sup>, Sol De Jesus, M.D.,<sup>a,i</sup> Jonathan Hakun<sup>a,i</sup>, Lan Kong, Ph.D.,<sup>h</sup> Yang Yang, Ph.D.,<sup>a,i</sup> Bethany Snyder,<sup>a,i</sup> Sridhar Duvvuri, Ph.D.,<sup>j</sup> David L. Gray, Ph.D.,<sup>j\*\*</sup> and Xuemei Huang, M.D. Ph.D.,<sup>a,b,d,e,f,g,i</sup>

Departments of Neurology,<sup>a</sup> Pharmacology,<sup>b</sup> Medicine,<sup>c</sup> Humanities,<sup>d</sup> Radiology,<sup>e</sup> Neurosurgery,<sup>f</sup> Kinesiology,<sup>g</sup> Public Health Sciences,<sup>h</sup> and the Translational Brain Research Center,<sup>i</sup> Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033 USA

and

Cerevel Therapeutics LLC,<sup>j</sup> Cambridge, MA, 02141 USA

*\*These authors contributed equally to this study*

*\*\*Currently Chief Scientific Officer, Inscopix, Palo Alto, CA*

*Running title: D<sub>1</sub> agonists in late-stage Parkinson's disease*

### Correspondence to the following authors:

Mechelle M. Lewis, Ph.D. Penn State Hershey Medical Center 500 University Dr., H-037 Hershey, PA 17033-0850 Email: <a href="mailto:mml19@psu.edu">mml19@psu.edu</a>	Xuemei Huang M.D., Ph.D. Penn State Hershey Medical Center 500 University Dr., H-037 Hershey, PA 17033-0850 Email: <a href="mailto:xuemei@psu.edu">xuemei@psu.edu</a>
---	---

### Manuscript details

	Current	Permitted
Running title (characters)	45	45
Abstract (words)	239	250
Key words	7	4-10
Text	3,666	3,700
Figures and tables	5	5

## **ABSTRACT**

**Background:** Current pharmacotherapy has limited efficacy and/or intolerable side effects in late-stage Parkinson's disease (LSPD) patients whose daily life depends primarily on caregivers and palliative care. Clinical metrics inadequately gauge efficacy in LSPD patients.

**Objective:** Explore if a  $D_{1/5}$  dopamine agonist will have efficacy in LSPD that will be detected most sensitively by caregivers in a phase I study.

**Methods:** A double-blind controlled phase Ia/b study compared the  $D_{1/5}$  agonist PF-06412562 to levodopa/carbidopa in six LSPD patients. Throughout the study, caregivers were with the patients. Assessments included standard quantitative scales of motor function (MDS-UPDRS-III), alertness (Glasgow Coma and Stanford Sleepiness Scales), and cognition (Severe Impairment and Frontal Assessment Batteries) at baseline (Day 1) and thrice daily during drug testing (Days 2 and 3). Clinicians and caregivers completed clinical impression of change questionnaires, and caregivers participated in a qualitative exit interview. Blinded triangulation of quantitative and qualitative data was used to integrate findings.

**Results:** Neither traditional scales, nor clinician impression of change, detected consistent differences between treatments in the five participants who completed the study. Conversely, the overall caregiver data strongly favored PF-06412562 over levodopa in four of five patients. The most meaningful improvements converged on motor, alertness, and engagement.

**Conclusion:**  $D_{1/5}$  agonists may offer potential benefit for LSPD patients. Caregiver perspectives with mixed method analyses may overcome limitations in standard rater/clinician-based evaluations. Further studies are warranted and need to integrate caregiver input as an essential component of outcome evaluations.

**Trial Registration#:** ClinicalTrials.gov: NCT03665454

**Key Words:** late-stage Parkinson's disease,  $D_1$  agonist, mixed methods, quantitative data, qualitative data, motor function, alertness/engagement

## INTRODUCTION

Parkinson's disease (**PD**) is characterized clinically by motor and non-motor symptoms. Despite research advances related to disease modifying therapy, symptomatic therapy using the dopamine precursor levodopa remains the cornerstone of therapy.<sup>1</sup> Unfortunately, progressive dopamine neuron loss markedly decreases bioconversion of levodopa to dopamine in the striatum but not mesolimbic areas, thereby decreasing efficacy and increasing side effects.<sup>2</sup> Additionally, potential “off-target” effects from dopamine formation in other monoamine neurons may cause side effects such as drowsiness and hallucinations.<sup>3-6</sup> Late-stage PD (**LsPD**) patients also experience many non-motor symptoms including anxiety/depression, pain, sleep disorders, cognitive decline, apathy, and social withdrawal,<sup>7,8</sup> some of which predate motor dysfunction.<sup>9</sup>

As PD patients advance to LsPD, there is a high burden for family and caregivers, and higher healthcare costs compared to early- and mid-stage (sometimes called advanced) patients.<sup>10-15</sup> There have been no prior controlled trials of drugs in LsPD patients due in part to the perceived fragility of the patients, lack of validated assessment tools for LsPD, and no accepted target that might mediate symptomatic benefit in patients where levodopa has limited efficacy. Because post-synaptic cytoarchitecture in LsPD patients is largely preserved despite dopamine neuron degeneration, targeting one or more of the post-synaptic dopamine receptor populations theoretically could offer marked therapeutic benefit.

Although many “dopamine agonists” are approved clinically and have some utility in earlier-stages of PD, they have inferior efficacy to levodopa and intolerable side effects in LsPD.<sup>16,19,20</sup> The term “dopamine agonist,” however, is misleading -- currently approved “dopamine agonists” are selective for dopamine D<sub>2</sub>-like receptors (e.g., see Supplemental Table A).<sup>16-18</sup> There is compelling neurobiological and pharmacological evidence for the potential of D<sub>1</sub> receptor-selective agonists in LsPD.<sup>19,21,22</sup> This is supported by experimental data in severe MPTP-treated non-human primates (NHPs)<sup>23,24</sup> and mid-stage PD patients.<sup>25,26</sup> The classical experimental D<sub>1</sub> agonists, however, contained a catechol-moiety that came with significant pharmaceutical liabilities.<sup>19</sup> Newer D<sub>1</sub> agonists have overcome this limitation<sup>27</sup> and shown efficacy in early- or mid-stage PD patients.<sup>28-31</sup> Thus, they also may have utility in LsPD patients.

Our search of the literature found no prior interventional studies conducted in LsPD. The accessibility of an orally available D<sub>1/5</sub> partial agonist PF-06412562 (*henceforth* PF-2562) allowed us

first to evaluate the safety of a  $D_{1/5}$  agonist in a very short (two-day) feasibility phase I pilot study of LsPD patients whose results were reported.<sup>32</sup> We now explore the efficacy of PF-2562 from that study using several *a priori* postulates. The first was a primary focus on caregiver impressions<sup>33-36</sup> because they were most familiar with patient behavior. In addition, standard clinical metrics obtained over the two-day study were less likely to capture meaningful changes in LsPD patients who had severe multi-domain disability. Finally, a convergent mixed methods design was used that involved collecting both quantitative and qualitative data, and comparing and contrasting findings.<sup>37</sup>

## PATIENTS AND METHODS

### *Study design, subjects, and randomization*

This study was conducted at PennStateHealth (PSH) in compliance with the ethical principles of the Declaration of Helsinki and guidelines for Good Clinical Practice issued by the International Conference on Harmonization. It was reviewed and approved by the US Food and Drug Administration and PSH Institutional Review Board. All participants and/or their caregivers provided signed informed consent. Details of subject recruitment, inclusion and exclusion criteria, baseline medical, protocol information, and safety data were published in a previous report.<sup>32</sup> Briefly, all participants were recruited from our Movement Disorders clinic or via a local PD support group and met published diagnostic criteria.

All LsPD subjects had disease duration  $>15$  y and Hoehn & Yahr stages  $\geq IV$ , either “on” or “off” levodopa. Our criteria were similar to those used by Coelho and Ferreira,<sup>38</sup> but differed from others who have used this term less specifically (e.g., disease duration  $<5$  y and Hoehn & Yahr stages II-III<sup>39</sup>). As a condition of their participation, all subjects were informed that regardless of response to PF-2562, they would not be permitted to continue taking PF-2562. After informed consent, participants and caregivers were admitted to the Clinical Research Center (CRC) for four days during two consecutive weeks. To maximize comfort, levodopa/carbidopa (for parkinsonian symptoms), acetaminophen (for pain), ondansetron (for nausea), and diphenhydramine (for allergies) were given throughout the study when needed.

Eligible participants were randomized to either PF-2562 (Sequence A) or levodopa (Sequence B) during the first test period using a 1:1 random allocation sequence, and then crossed-over to the other drug during the second test period (see Supplemental Figure A). Participants, caregivers, and investigators were blinded to sequence assignment, and participants received identical numbers of pills

(i.e., containing PF-2562, levodopa, and/or placebo) that were administered at the same time during each sequence. Specifically, following overnight levodopa/dopamine agonist washout and baseline evaluation on Day 1, participants assigned Sequence A received PF-2562 (25 mg at ~0900 h and 20 mg 4 h later) on Days 2-3 during Test Period 1, whereas they received encapsulated Sinemet (carbidopa/levodopa 25/100 mg) 3-4 times (depending on pretrial regimen) 4 h apart on Days 2-3 during Test Period 2. Participants assigned Sequence B received Sinemet in Test Period 1 and PF-2562 in Test Period 2. On Day 4, all participants resumed pre-trial treatment and were discharged after demonstrating no significant complications.

### ***Choice of study compound***

The initial pilot study focused on establishing the safety and tolerability of a D<sub>1</sub> agonist in LSPD, thereby querying the feasibility of conducting clinical trials in LSPD. Among the available D<sub>1</sub> agonists, PF-2562 was selected because it caused acute antiparkinsonian effects in 13 PD patients and was well-tolerated at a 50 mg oral dose ( $t_{1/2}$ =6.4 h) split into 30 and 20 mg doses given four hours apart.<sup>29</sup> This informed the current study design and split-dose regimen involving a short in-patient stay and cross-over design. Tavapadon, a related D<sub>1</sub> agonist, is dosed via a titration regimen to reach efficacious drug levels,<sup>31</sup> and the limitations of this pilot study did not allow for extended in-clinic stays to accommodate titration.

### ***Quantitative data and metrics***

We included five standard quantitative scales<sup>40-43</sup> for specific efficacy domains representing: motor [MDS-UPDRS motor scale (MDS-UPDRS-III)]; alertness [Glasgow Coma (GCS) and Stanford Sleepiness (SSS) Scales]; and cognition [(Severe Impairment (SIB), and Frontal Assessment (FAB) Batteries)]. Scores were obtained three times each on Days 2-3: prior to drug administration and then one hour after the first and second dose. We also evaluated sleep using polysomnography (PSG), except in two participants (3 and 4) with deep brain stimulation due to disruption of EEG signals captured during PSG. From these data, “sleep efficiency” was selected as the most global/comprehensive metric to report.

As detailed in our previous report,<sup>32</sup> movement disorder clinicians and caregivers completed an adapted validated global clinical impression (GCI) scale designed to assess severity (GCI-S) or change (GCI-C). On Day 1, clinicians evaluated patients’ history and exam (H&P), and summarized it as a single GCI-S score ranging from 1=normal/not ill to 7=extremely ill. Caregivers completed a baseline GCI-S on Day 1 based on their knowledge of the participant’s disease at home that included 17 items we

summarized as one score ranging from 0-102. At the end of Days 2-3, both caregivers and clinicians completed the GCI-C questionnaire that included 17 items scored on a 7-point Likert scale (-3=marked worsening; 0=no change; 3=marked improvement). Clinicians completed this assessment based on interviews with caregivers and daily examination of patients. As pre-specified, Day 3 metrics were used for final analyses to avoid likely confounders such as excitement/noise/environment changes on Day 2.

### ***Qualitative interviews***

Qualitative data collection was chosen to capture broad, nuanced experiences, observations, and perspectives of caregivers regarding potential efficacy and/or side effects. Semi-structured caregiver interviews (30-60 minutes) were conducted by a trained qualitative research assistant at the end of Day 3. Responses were audio-recorded and transcribed verbatim. Interviews explored the extent to which caregivers perceived patient response to study drug (if any) and adverse effects compared to patient status at baseline. The interview guide used open-ended questions to elicit first general observations from caregivers and then probed specific domains of motor, alertness, cognition, and sleep (*vide infra*).

### ***Convergent mixed methods design***

Convergent mixed methods designs collect both quantitative and qualitative data for a ‘domain’ of interest and then compares and contrasts the conclusions from each dataset (‘merging’) to reach a comprehensive conclusion.<sup>44</sup> At study conception, pre-selected domains were guided by our clinical experiences with LSPD patients and extant literature. Table 1 lists these domains of interest (motor, alertness, cognition, sleep, and clinician/caregiver impression of change), and the quantitative and qualitative measures that corresponded to each domain. Domains were analyzed separately and conclusions drawn independently. Blinded data then were integrated by merging findings and seeking points of convergence or divergence in the conclusions.<sup>44,45</sup> This mixed methods approach establishes stronger credibility and validity to the findings when convergence of conclusions is established and opportunities to extract lessons when divergence is detected.<sup>44,45</sup>

### ***Analysis***

#### **Quantitative analysis**

Quantitative scales provided either one score (GCS, SSS, and sleep efficiency) or several that were summed (SIB, FAB, and MDS-UPDRS-III) for each participant. The score at the start of Day 2 prior to study drug administration then was subtracted from the score at the end of Day 3 to evaluate change. Both clinician and caregiver GCI-C scores also were captured. For the purposes of this study, we included motor, alertness, cognition, and sleep scores. Scores are presented for each participant in

this pilot study of six subjects. Based on pre-determined efficacy assessment, the primary endpoint was caregiver ratings that were analyzed using a paired Student's t-test (two-tailed  $\alpha=0.05$ ).

### Qualitative analysis

Conventional content analysis including data transformation was used to evaluate the data.<sup>44</sup> Published guidelines for methodological rigor of qualitative analysis were followed to ensure attention to the truth-value, applicability, consistency, and neutrality of findings.<sup>44,46</sup> Three independent, blinded analysts used qualitative software (NVivo Ver. 11.0, QSR International, Melbourne Australia) to code and analyze the data. Analytic details are provided in Supplemental Text A.

### Mixed methods integration

Joint displays were constructed to compare quantitative efficacy outcomes with results from the transformed qualitative data for each participant completing the study (n=5). The study team reviewed conclusions from both the quantitative and qualitative datasets to ascertain an integrated conclusion of the preliminary efficacy of PF-2562.<sup>45</sup>

### ***Data sharing***

De-identified data supporting the findings of this study are available upon reasonable request from corresponding author XH. The data are not publicly available due to privacy or ethical restrictions. All requests must be in writing and will be evaluated in a timely manner by the TBRC executive team.

## **RESULTS**

### ***Participants***

Six subjects met inclusion criteria (demographics in Supplemental Table B). Patients had a mean age of 73.5 ( $\pm 4.5$  SD) y and two participants were female. Consistent with protocol inclusion criteria, patient Hoehn & Yahr stages all were  $>4$  in the 'on' state. No subject required levodopa rescue during the PF-2562 week, whereas one participant was administered rescue medication during the levodopa week (subject 4, 0.5 100/25 mg levodopa/carbidopa tablet on Day 2, 1 on Day 3). Of the six patients who were randomized, one (subject 6, disease duration 19 y) withdrew after the first arm because of blood pressure fluctuations the clinical team felt were related to the interaction of test drug with baseline dehydration, related kidney dysfunction, and autonomic dysfunction.<sup>32</sup> This patient's data is excluded from these efficacy analyses. The remaining five patients completed both arms of the study.

Key narrative phrases from caregiver interviews qualitatively describe the patient's baseline functional status (Supplemental Table B). Four of five patients (subjects 1, 3, 4, and 7) represented

classic LsPD patients and had disease durations ranging from 15-23 y. All patients had been treated with symptomatic drugs and two with deep brain stimulation. In addition to motor disability and requirement of walker and/or wheelchair use, all patients had varying challenges in maintaining normal sleep/wake cycles, being alert and engaged during daytime, and all displayed clinically significant cognitive dysfunction.

Subject 8 had the longest disease duration (32 y). All drugs including levodopa had caused intolerable side effects and thus this patient had not been treated with any parkinsonian drugs for three years prior to study enrollment. On most days, he was in unarousable “deep sleep,” but was able to reflexively suck and swallow if his mouth was stimulated with a straw or food in a more “awake” state. Because of his atypical background and long survival without dopaminergic medication, we highlight his response to treatment in subsequent sections because it may provide unique insight into the pathophysiology of LsPD.

### ***Quantitative results***

Standardized scales assessing motor function, alertness, cognition, and sleep did not detect a clear pattern of differences between levodopa and PF-2562 (see details in Supplemental Text A and Table 2). Clinician scores were more variable than those from caregivers for both levodopa and PF-2562 (Figure 1A), and caregivers rated PF-2562 consistently better than levodopa ( $p=0.007$ ; Figure 1B). This offered initial evidence that PF-2562 may provide improved efficacy based on caregiver scores.<sup>32</sup>

### ***Qualitative caregiver interview results***

Blinded analysis of the transcripts revealed significant variability in patients’ baseline functional status (see details in Supplemental Text B and Table 3). Notably, caregivers did not distinguish explicitly among alertness, attention, and cognition according to qualitative analyses. Therefore, these domains were collapsed as ‘patient overall engagement’ in the mixed methods joint display. Results of the qualitative data transformations (improved, worsened, unchanged) are shown in Table 3, along with quotations from caregivers describing the changes they noticed within each domain. Overall, the qualitative data suggested that PF-2562 improved cognitive engagement and motor domain status (balance, weakness, and rigidity) in the four typical LsPD subjects.

Qualitative analyses also suggested that PF-2562 may improve facial expression and sleep to varying degrees, although qualitative analysis of sleep was challenging due to highly variable caregiver descriptions (e.g., judgment of sleep quality based on different aspects such as breathing, apneas,



duration, depth of napping, restlessness, vocalizations). All caregivers commented that some aspect of the environment may have impacted results. For example, caregiver-1 said: “*I would attribute some of the alertness... to the rigid schedule [that] does keep him at his best...the constant stimulation of people is different than at home.*” Similarly, caregiver-7 noted: “*Here the chair styles are a little bit different, a little deeper and the floors are a little slicker, footwear was a little different.*”

Subject 8 responded dramatically to levodopa but not PF-2562 (see Tables 2-3). Prior to unblinding, both the clinician and caregiver felt Test Period 2 (levodopa) was far superior to Test Period 1 (PF-2562). After discussion with the research ethics consult service, it was decided it was our responsibility to convey these results to the family. This was done and the patient’s family decided to restart levodopa. They reported levodopa had no beneficial effect and the patient remained in a “deep sleep” state.

### ***Mixed methods results***

Integration of quantitative and qualitative data suggested a convergent finding that caregivers favored PF-2562 in four of five patients who completed the study (Table 4). Caregiver observations suggested that alertness and engagement/cognition domains had the most dramatic changes in the four typical LsPD participants. Caregivers also noted that environmental factors likely played a role in the improvements during both weeks. Additionally, the qualitative data uncovered a potential side effect that was not measured discretely in questionnaires (‘twitching’) or detected on quantitative measures. This observation was reported during both the levodopa and PF-2562 testing periods. No caregivers or patients commented specifically on dyskinesia or a special “feeling” that would suggest they were taking levodopa.

Overall, caregivers were consistent in their quantitative observations with minimal variability, whereas clinician impressions displayed substantial variability and diverged from caregiver impressions in two of five patients. The rater-dependent standard metrics detected no differences and were not contributory to the overall results.

## **DISCUSSION**

LsPD patients have many unmet needs, and supportive and palliative care increasingly have been recognized as the best option (e.g., reviews<sup>47,48</sup>). This first controlled interventional study in LsPD patients explored if a D<sub>1</sub> agonist may have potential benefits in this population exceeding those of

palliative care.<sup>24</sup> We included caregiver perspectives and used mixed methods<sup>49,50</sup> to identify potential efficacy domains of PF-2562 based on the premise that: 1) traditional clinical tools would be relatively insensitive given the small number of patients and short duration/evaluation period,<sup>38</sup> and 2) PD patients and their neurologists differ markedly in assessing physical, psychological, and other domains that predict quality of life (QoL).<sup>51</sup> Our data showed caregivers captured potential benefits of PF-2562 in LsPD patients in ways standard clinical metrics did not. Moreover, mixed methods allowed transformation of semi-structured caregiver observations to quantifiable metrics and identified key domains of improvement (motor, alertness, and cognitive engagement) that warrant future attention.

### ***The promise of D<sub>1</sub> agonists in LsPD***

Lack of effective treatments for LsPD patients has been a major motivation for seeking disease-modifying therapies<sup>52</sup> whose clinical trials have focused on enrolling newly-diagnosed or early PD patients. LsPD patients (~5% of the PD population) have major unmet medical needs and are excluded from most clinical trials by both design and their overall health status. In NHP models<sup>23</sup> and PD itself,<sup>25</sup> however, selective D<sub>1</sub>-like agonists are at least equally effective to levodopa.<sup>53</sup> Importantly, the full D<sub>1</sub> agonist dihydroxydine markedly attenuated parkinsonian motor signs in MPTP-treated NHPs with disability analogous to subjects in the current study, whereas neither levodopa, nor the D<sub>2/3</sub> agonist bromocriptine, was effective.<sup>24</sup>

The availability of newer generation D<sub>1/5</sub> agonists for clinical trials renewed a broad interest in targeting D<sub>1</sub>-like receptors to improve cognitive function in multiple disease states (see review<sup>54</sup>). The current data provide tantalizing evidence that this benefit may extend to LsPD patients. As with motor signs, increased apathy as PD progresses also is observed commonly.<sup>55</sup> PD apathy and impulse control disorders may be opposite motivational expressions caused by hypo- and hyperdopaminergia, with apathy resulting from hypodopaminergia along with anhedonia, anxiety, and depression. Since the approved D<sub>2/3</sub> agonists are relatively ineffective, the current data suggest D<sub>1</sub> agonists also may be effective for motivational deficits in LsPD.

The unique background and response of subject 8 were profound and possibly informative. Since this individual had been largely unresponsive to all treatment in prior years, the dramatic improvement during the levodopa week could be random. It is possible, however, the participant had somehow re-sensitized to levodopa after a three year “drug holiday.” This seems unlikely since there was no effect when the family resumed levodopa. Although highly speculative, another hypothesis is that the two-day

period of PF-2562 administration “primed” dopamine circuitry (e.g., by improving sleep structure) to respond more normally to even small amounts of dopamine from a subsequent levodopa challenge six days later. Coupled with the very consistent beneficial responses of the other four patients, the hypothesis is a high priority for further testing, as there are tens-of-thousands of such LsPD patients in the US alone.

### ***The importance of caregiver perspectives***

Most clinical trials rely upon informed clinician judgement based on validated instruments and (when available) imaging/molecular/biochemical markers, but no validated standard scales exist for LsPD.<sup>38</sup> Clinical ratings of complex behaviors necessarily involve short evaluation epochs with inherent inter-individual and inter-location variability. Prizer et al.<sup>51</sup> found PD patients and their neurologists differed markedly in assessing physical, psychological, and other domains predicting QoL, and the value of caregiver input has been recognized previously.<sup>33-36,51,56</sup> In our study, alertness, social interaction, and QoL improvements reported by caregivers reflect changes that are critical to palliative care in LsPD. Decreasing apathy, increasing arousal, or similar improvement in non-motor and motor function could have wide applicability in the absence of “cures.”

In our study, caregiver observations also were more consistent and less variable than experienced physicians. This is not surprising since caregivers were intimately familiar with nuanced baseline patient behaviors, were able to provide insight and context for typical or atypical behavioral observations, and were at the bedside 24/7 during the study. It also is noteworthy that blinded caregivers consistently identified the levodopa week as not being remarkably different from home baseline. This gives credence to the caregivers’ observations and objectivity.

### ***Utility of mixed methods in a phase I study***

Mixed method approaches in clinical trials often are limited to pre-trial use or assessing implementation issues such as recruitment,<sup>57</sup> and seldom have been used to examine drug trial outcomes.<sup>58</sup> Our approach revealed efficacy endpoints and observations that were not captured by questionnaires with pre-specified areas of inquiry or anticipated prior to study initiation. The qualitative data added texture to quantitative caregiver evaluations, and their convergence provides compelling data for additional studies investigating PF-2562 to enhance both motor function and cognitive engagement. Future studies should consider integrating mixed method strategies at the phase I stage that may lead both to cost savings and more effective selection of efficacy endpoints in phase II-III trials.

### ***Limitations and future directions***

We are cognizant of the limitations of the current report, but these should be viewed in context. With no prior experience available for interventional studies in LSPD, the design<sup>32</sup> had to focus on the safety and feasibility, thus limiting both the number of subjects and permitted treatment duration (two days). Efficacy was a second primary endpoint, but it could be evaluated only if the *a priori* safety concerns had not terminated the study. Moreover, the study was completely blinded, all data were locked, and the analysis plan decided *a priori*. The finding of an average significant improvement required excluding the data from subject 8. We feel this was justified as described earlier. It is noteworthy that for the other four subjects, PF-2562 could have worsened them or had no effect, yet these four subjects all had meaningfully better response to PF-2562 than levodopa. We feel that these data provide compelling evidence for further investigation into the potential value of a D<sub>1/5</sub> agonist in LSPD using increased numbers of subjects and longer drug administration periods. Such studies must incorporate caregiver perspectives that should be conducted at home to eliminate environmental influences on patient behavior. Finally, the few currently available D<sub>1/5</sub> agonists differ in pharmacological properties (i.e., both intrinsic activity at canonical pathways or functional selectivity).<sup>59,60</sup> As experience with D<sub>1/5</sub> agonists in this population is gained, there may be ways to choose compounds with specific profiles for maximal therapeutic benefit.<sup>61-63</sup>

## **ACKNOWLEDGEMENTS**

We express deep gratitude to all of the patients and their caregivers for participating in the study. The completion of the study was made possible by an exceptional team including Shirlynn Mottilla, Nancy Handley, Brenda Hershey-Fell, Lyndsey Houser, Carrie Criley, Patricia Cain, Sue Kocher, Lisa Zeno, Alison Enimpah, Kelly Hoffman, Lori Martin, Brynn Vanderveer, Dina Angello, Kiley Klock, Fiona Fortman, Sandra Franz, Crystal DeMedici, Sarah Debold, and Natalya Knapp. We thank Margaret Hopkins and Dr. K. Randy Young for assisting with the qualitative and mixed methods analysis; Dr. Andrew Foy for consulting on cardiology and ECG questions raised during screening and the conduct of the project; Sara Marlin for serving as our data monitor; and Dr. Gary Thomas for serving on the Data Safety Board (DSB). In addition, we thank Dr. Jennifer McCormick, research ethicist, for providing critical input on our decision to unblind participant 8. This work was supported by a grant from Pfizer Central Research who also supplied test drug and placebo. This work also was supported in part by the National Institute of Neurological Disorders and Stroke and Parkinson's Disease Biomarker Program (NS060722, NS082151 to XH), and the Penn State National Center for Advancing Translational Sciences, National Institute of Health, through the grant UL1 TR002014. The authors also thank the Quantitative Mixed Methods Center of the Penn State College of Medicine for their assistance with the mixed methods analysis. All analyses, interpretations, and conclusions are those of the authors and not the research sponsors.

## **FINANCIAL DISCLOSURE/CONFLICT OF INTEREST AND FUNDING SOURCE**

This study was funded in part, and drug supplied, by Pfizer, Inc. The study also was supported by the Penn State College of Medicine Translational Brain Research Center. All analyses, interpretations, and conclusions are those of the authors and not the research sponsors. Drs. Huang (PI) and Mailman declared a potential conflict of interest (COI) due to existing patents related due to the discovery or use of D<sub>1</sub> agonists, although this technology is not in, or has planned, commercial development. Drs. Huang and Mailman have had past travel expenses paid by Cerevel Therapeutics. Dr. Mailman is a member of the tavapadon advisory board of Cerevel. Drs. Huang and Mailman did not participate in consenting subjects, were not involved with the Data Safety Board (DSB, composed of three investigators and three clinicians), and did not participate in data analysis until the data were locked. Dr. Huang worked closely with Drs. De Jesus (a movement disorder specialist) and Van Scoy (a pulmonary and critical care physician) to provide the best care for participants throughout the study.

Drs. Huang or De Jesus provided blinded ratings for the clinician global impression of change based on their clinical availability.

## **AUTHOR CONTRIBUTIONS**

The trial design was initiated by the authors from Penn State and finalized in collaboration with the Pfizer authors as listed below.

1. Research project: A: Conception, B: Organization, C: Execution
2. Data and Statistical analysis: A: Design, B: Execution, C: Review and critique
3. Manuscript preparation: A: Writing the first draft, B: Review and critique

Mechelle M. Lewis: 1A, 1B, 1C, 2A, 2C, 3A, 3B

Lauren Jodi Van Scoy: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B

Sol De Jesus: 1C, 2C, 3B

Jonathan Hakun: 1B, 1C, 3B

Lan Kong: 2A, 2B, 2C, 3B

Yang Yang: 2C, 3B

Bethany Snyder: 1B, 1C, 2B, 2C, 3B

Sridhar Duvvuri: 2A, 2C

David Gray: 1A, 2A, 2C, 3B

Richard Mailman, 1A, 1B, 2C, 3A, 3B

Xuemei Huang: 1A, 1B, 1C, 2A, 2C, 3A, 3B.

## FINANCIAL DISCLOSURES

- Mechelle M. Lewis: Received funding from the National Institutes of Health (R01 ES019672, U01 NS082151, U01 NS112008), the Michael J. Fox Foundation, the Michael J. Fox Foundation for Parkinson's Research, Alzheimer's Association, Alzheimer's Research UK, and the Weston Brain Institute, Bristol Myers Squibb/Biogen, Pfizer, and the Department of Defense.
- Lauren Jodi Van Scoy: Received funding from the National Institute of Nursing Research Institute (R01 MD04141, R21 NR017259, 2R01 NR012757-06), the Parker B. Francis Family Foundation, the John and Wauna Harman Family Foundation, Canadian Institute of Health Research, Society for Critical Care Medicine, and Association for Clinical Pastoral Education.
- Sol De Jesus: Has received funding from the National Institute for Neurological Disorders and Stroke (NINDS), Bristol Myers Squibb, Pfizer, as well as consultant fees from Medtronic Inc. and Boston Scientific.
- Jonathan Hakun: Has received funding from the National Institute of Aging (NIA, R00 AG056670).
- Lan Kong: Received funding from the National Institutes of Health (R01 ES019672, U01 NS082151, U01 NS112008), the Michael J. Fox Foundation for Parkinson's Research, Alzheimer's Association, Alzheimer's Research UK, and the Weston Brain Institute.
- Yang Yang: Received funding from the National Institutes of Health (R01 AG071675).
- Bethany Snyder: Has no conflict of interest to disclose.
- Sridhar Duvvuri: Was an employee and shareholder of Pfizer, Inc at the time of study design and initiation. He is now an employee of Cerevel Therapeutics.
- David Gray: Was an employee and shareholder of Pfizer, Inc at the time of study design and initiation. He was an employee and shareholder of Cerevel Therapeutics LLC during the analyses of these data.
- Richard B. Mailman: Receives funding on related subjects from the National Institutes of Health (R01 NS105471 and R01 AG071675). Holds patents related to D<sub>1</sub> dopamine agonists as therapeutic agents that have now been abandoned. Past D<sub>1</sub>-related grant, consulting, and travel from Pfizer Central Research (none since 2017). He received travel expenses from Cerevel Therapeutics in 2019, and is now on the tavapadon advisory board. *Unrelated to this study*: Past expert witness or consultant to several law firms and US Department of Justice. Past consultant to Jazz Pharma (publishing costs only). The Penn State College of Medicine actively manages Dr. Mailman's disclosed potential conflicts of interest.
- Xuemei Huang: Received funding from the National Institutes of Health (R01 ES019672, U01 NS082151, U01 NS112008), the Michael J. Fox Foundation for Parkinson's Research, Alzheimer's Association, Alzheimer's Research UK, and the Weston Brain Institute, Bristol Myers Squibb/Biogen, Pfizer, and the Department of Defense. She has an interest in patents related to D<sub>1</sub> technology that are not being actively prosecuted; this conflict of interest has been disclosed to, and managed by, the Penn State University.

## USE OF VERTEBRATE ANIMALS OR HIGHER NON-VERTEBRATE SPECIES

This study was done in human Parkinson's disease patients. No laboratory animals were used.

## REFERENCES

- 1 Cotzias GC, Van Woert MH & Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. *N Engl J Med* **276**, 374-379, doi:10.1056/NEJM196702162760703. <https://www.ncbi.nlm.nih.gov/pubmed/5334614>. PMID:
- 2 Goldstein M, Lieberman A & Pearson J (1982) Relatively high levels of dopamine in nucleus accumbens of levodopa treated patients with Parkinson's disease. *J Neural Transm* **54**, 129-134, doi:10.1007/BF01249286. <https://www.ncbi.nlm.nih.gov/pubmed/6125563>. PMID:
- 3 Barone P (2010) Neurotransmission in Parkinson's disease: beyond dopamine. *Eur J Neurol* **17**, 364-376, doi:10.1111/j.1468-1331.2009.02900.x. <https://www.ncbi.nlm.nih.gov/pubmed/20050885>. PMID:
- 4 Munoz A, Lopez-Lopez A, Labandeira CM & Labandeira-Garcia JL (2020) Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson's Disease and Adverse Effects of L-DOPA. *Front Neuroanat* **14**, 26, doi:10.3389/fnana.2020.00026. <https://www.ncbi.nlm.nih.gov/pubmed/32581728>. PMID: PMC7289026
- 5 Shin E, Tronci E & Carta M (2012) Role of Serotonin Neurons in L-DOPA- and Graft-Induced Dyskinesia in a Rat Model of Parkinson's Disease. *Parkinson's disease* **2012**, 370190, doi:10.1155/2012/370190. <https://www.ncbi.nlm.nih.gov/pubmed/22762012>. PMID: PMC3384974
- 6 Navailles S, Carta M, Guthrie M & De Deurwaerdere P (2011) L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease. *Cent Nerv Syst Agents Med Chem* **11**, 305-320, doi:10.2174/1871524911106040305. <https://www.ncbi.nlm.nih.gov/pubmed/22117594>. PMID:
- 7 Fox S, Gannon E, Cashell A, Kernohan WG, Lynch M, McGlade C, O'Brien T, O'Sullivan SS, Sweeney C & Timmons S (2015) Survey of Health Care Workers Suggests Unmet Palliative Care Needs in Parkinson's Disease. *Mov Disord Clin Pract* **2**, 142-148, doi:10.1002/mdc3.12133. <https://www.ncbi.nlm.nih.gov/pubmed/30363946>. PMID: PMC6183248
- 8 Lex KM, Larkin P, Osterbrink J & Lorenzl S (2018) A Pilgrim's Journey-When Parkinson's Disease Comes to an End in Nursing Homes. *Front Neurol* **9**, 1068, doi:10.3389/fneur.2018.01068. <https://www.ncbi.nlm.nih.gov/pubmed/30619034>. PMID: PMC6297137
- 9 Visanji N & Marras C (2015) The relevance of pre-motor symptoms in Parkinson's disease. *Expert review of neurotherapeutics* **15**, 1205-1217, doi:10.1586/14737175.2015.1083423. <https://www.ncbi.nlm.nih.gov/pubmed/26416397>. PMID:
- 10 Kaltenboeck A, Johnson SJ, Davis MR, Birnbaum HG, Carroll CA, Tarrant ML & Siderowf AD (2012) Direct costs and survival of medicare beneficiaries with early and advanced Parkinson's disease. *Parkinsonism Relat Disord* **18**, 321-326, doi:10.1016/j.parkreldis.2011.11.015. <https://www.ncbi.nlm.nih.gov/pubmed/22177623>. PMID:
- 11 Low JA, Pang WS, Chan DK & Chye R (2003) A palliative care approach to end-stage neurodegenerative conditions. *Ann Acad Med Singap* **32**, 778-784. <https://www.ncbi.nlm.nih.gov/pubmed/14716946>. PMID:
- 12 Thomas S & MacMahon D (2004) Parkinson's disease, palliative care and older people: Part 1. *Nurs Older People* **16**, 22-26, doi:10.7748/nop2004.03.16.1.22.c2290. <https://www.ncbi.nlm.nih.gov/pubmed/15045859>. PMID:



- 13 Connor K, Cheng E, Siebens HC, Lee ML, Mittman BS, Ganz DA & Vickrey B (2015) Study protocol of "CHAPS": a randomized controlled trial protocol of Care Coordination for Health Promotion and Activities in Parkinson's Disease to improve the quality of care for individuals with Parkinson's disease. *BMC Neurol* **15**, 258, doi:10.1186/s12883-015-0506-y. <https://www.ncbi.nlm.nih.gov/pubmed/26670300>. PMID: PMC4681014
- 14 Bouca-Machado R, Titova N, Chaudhuri KR, Bloem BR & Ferreira JJ (2017) Palliative Care for Patients and Families With Parkinson's Disease. *Int Rev Neurobiol* **132**, 475-509, doi:10.1016/bs.irn.2017.02.017. <https://www.ncbi.nlm.nih.gov/pubmed/28554419>. PMID:
- 15 Di Luca DG, Singer C & Margolesky JH (2020) Palliative Care in Parkinson Disease-Is It Beneficial for All? *JAMA Neurol* **77**, 1450, doi:10.1001/jamaneurol.2020.3212. <https://www.ncbi.nlm.nih.gov/pubmed/32897295>. PMID:
- 16 Mailman RB & Huang X (2007) Dopamine receptor pharmacology. *Handb Clin Neurol* **83**, 77-105, doi:10.1016/S0072-9752(07)83004-1. <https://www.ncbi.nlm.nih.gov/pubmed/18808911>. PMID:
- 17 Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA & Millan MJ (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. *Journal of Pharmacology and Experimental Therapeutics* **303**, 805-814. PM:12388667. PMID:
- 18 Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA & Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. *J Pharmacol Exp Ther* **303**, 791-804, doi:10.1124/jpet.102.039867. <https://www.ncbi.nlm.nih.gov/pubmed/12388666>. PMID:
- 19 Mailman R, Huang X & Nichols DE (2001) Parkinson's disease and D1 dopamine receptors. *Curr Opin Investig Drugs* **2**, 1582-1591. <https://www.ncbi.nlm.nih.gov/pubmed/11763161>. PMID:
- 20 Konta B & Frank W (2008) The treatment of Parkinson's disease with dopamine agonists. *GMS Health Technol Assess* **4**, Doc05. <https://www.ncbi.nlm.nih.gov/pubmed/21289911>. PMID: PMC3011299
- 21 Huang X, Lawler CP, Lewis MM, Nichols DE & Mailman RB (2001) D1 dopamine receptors. *Int. Rev. Neurobiol* **48**, 65-139. <http://www.ncbi.nlm.nih.gov/pubmed/11526741>. PMID:
- 22 Mailman RB & Nichols DE (1998) Dopamine D1 receptor agonists as antiparkinson drugs. *Trends Pharmacol Sci* **19**, 255-256. <Go to ISI>://WOS:000075063700006. PMID:
- 23 Taylor JR, Lawrence MS, Redmond DE, Jr., Elsworth JD, Roth RH, Nichols DE & Mailman RB (1991) Dihydroxydopamine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. *European journal of pharmacology* **199**, 389-391, doi:10.1016/0014-2999(91)90508-n. <https://www.ncbi.nlm.nih.gov/pubmed/1680717>. PMID:
- 24 Mailman RB, Yang Y & Huang X (2021) D1, not D2, dopamine receptor activation dramatically improves MPTP-induced parkinsonism unresponsive to levodopa. *European journal of pharmacology* **892**, 173760, doi:10.1016/j.ejphar.2020.173760. <https://www.ncbi.nlm.nih.gov/pubmed/33279520>. PMID:
- 25 Rascol O, Blin O, Thalamas C, Descombes S, Soubrouillard C, Azulay P, Fabre N, Viallet F, Lafnitzegger K, Wright S, Carter JH & Nutt JG (1999) ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease. *Ann Neurol* **45**, 736-741, doi:10.1002/1531-

- 8249(199906)45:6<736::aid-ana7>3.0.co;2-f. <https://www.ncbi.nlm.nih.gov/pubmed/10360765>.  
PMCID:
- 26 Rascol O, Nutt JG, Blin O, Goetz CG, Trugman JM, Soubrouillard C, Carter JH, Currie LJ, Fabre N, Thalamas C, Giardina WW & Wright S (2001) Induction by dopamine D<sub>1</sub> receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. *Arch Neurol* **58**, 249-254, doi:10.1001/archneur.58.2.249.  
<https://www.ncbi.nlm.nih.gov/pubmed/11176963>. PMCID:
- 27 Gray DLF, Zhang L, Davoren J, Dounay AB, Viktorovich I, Lee C, Mente SR, O'Neil SV, Rogers BN & Subramanyam C (2018) HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS. USA patent US10077272 B2.
- 28 Gray DL, Allen JA, Mente S, O'Connor RE, DeMarco GJ, Efremov I, Tierney P, Volfson D, Davoren J, Guilmette E, Salafia M, Kozak R & Ehlers MD (2018) Impaired beta-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor. *Nature communications* **9**, 674, doi:10.1038/s41467-017-02776-7.  
<https://www.ncbi.nlm.nih.gov/pubmed/29445200>. PMCID: PMC5813016
- 29 Papapetropoulos S, Liu W, Duvvuri S, Thayer K & Gray DL (2018) Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration. *Neurodegener Dis* **18**, 262-269, doi:10.1159/000492498. <https://www.ncbi.nlm.nih.gov/pubmed/30453303>.  
PMCID:
- 30 Riesenbergr R, Werth J, Zhang Y, Duvvuri S & Gray D (2020) PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial. *Ther Adv Neurol Disord* **13**, 1756286420911296, doi:10.1177/1756286420911296.  
<https://www.ncbi.nlm.nih.gov/pubmed/32201505>. PMCID: PMC7066585
- 31 Sohur US, Gray DL, Duvvuri S, Zhang Y, Thayer K & Feng G (2018) Phase 1 Parkinson's Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated. *Neurol Ther* **7**, 307-319, doi:10.1007/s40120-018-0114-z.  
<https://www.ncbi.nlm.nih.gov/pubmed/30361858>. PMCID: PMC6283789
- 32 Huang X, Lewis MM, Van Scoy LJ, De Jesus S, Eslinger PJ, Arnold AC, Miller AJ, Fernandez-Mendoza J, Snyder B, Harrington W, Kong L, Wang X, Sun D, Delnomdedieu M, Duvvuri S, Mahoney SE, Gray DL & Mailman RB (2020) The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study. *Journal of Parkinson's disease* **10**, 1515-1527, doi:10.3233/JPD-202188.  
<https://www.ncbi.nlm.nih.gov/pubmed/32986682>. PMCID:
- 33 Miyasaki JM & Kluger B (2015) Palliative care for Parkinson's disease: has the time come? *Curr Neurol Neurosci Rep* **15**, 26, doi:10.1007/s11910-015-0542-4.  
<https://www.ncbi.nlm.nih.gov/pubmed/25795037>. PMCID:
- 34 Klietz M, Eichel HV, Staeger S, Kutschenko A, Respondek G, Huber MK, Greten S, Hoglinger GU & Wegner F (2021) Validation of the Parkinson's Disease Caregiver Burden Questionnaire in Progressive Supranuclear Palsy. *Parkinson's disease* **2021**, 9990679, doi:10.1155/2021/9990679. <https://www.ncbi.nlm.nih.gov/pubmed/34046156>. PMCID: PMC8128535
- 35 Gulunay A, Cakmakli GY, Yon MI, Ulusoy EK & Karakoc M (2020) Frequency of non-motor symptoms and their impact on the quality of life in patients with Parkinson's disease: a prospective descriptive case series. *Psychogeriatrics* **20**, 206-211, doi:10.1111/psyg.12489.  
<https://www.ncbi.nlm.nih.gov/pubmed/31782214>. PMCID:


- 36 Deck BL, Xie SX, Choi G, Rick J, Siderowf A, Rudovsky S, Chen-Plotkin A, Duda JE, Morley JF, Dahodwala N, Trojanowski JQ & Weintraub D (2019) Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants. *Mov Disord Clin Pract* **6**, 440-445, doi:10.1002/mdc3.12781. <https://www.ncbi.nlm.nih.gov/pubmed/31392244>. PMID: PMC6660222
- 37 Creswell JWC, J. David (2017) *Research design: Qualitative, quantitative, and mixed methods approaches*. Fifth edn, (Sage Publishing).
- 38 Coelho M & Ferreira JJ (2012) Late-stage Parkinson disease. *Nat. Rev. Neurol* **8**, 435-442, doi:nrneuro.2012.126 [pii];10.1038/nrneuro.2012.126 [doi]. <http://www.ncbi.nlm.nih.gov/pubmed/22777251>. PMID:
- 39 Santos-Garcia D, de Deus Fonticoba T, Suarez Castro E, Aneiros Diaz A & McAfee D (2020) 5-2-1 Criteria: A Simple Screening Tool for Identifying Advanced PD Patients Who Need an Optimization of Parkinson's Treatment. *Parkinson's disease* **2020**, 7537924, doi:10.1155/2020/7537924. <https://www.ncbi.nlm.nih.gov/pubmed/32269748>. PMID: PMC7128051
- 40 Panisset M, Roudier M, Saxton J & Boller F (1994) Severe impairment battery. A neuropsychological test for severely demented patients. *Arch Neurol* **51**, 41-45. <https://www.ncbi.nlm.nih.gov/pubmed/8274108>. PMID:
- 41 Dubois B, Slachevsky A, Litvan I & Pillon B (2000) The FAB: a Frontal Assessment Battery at bedside. *Neurology* **55**, 1621-1626. <https://www.ncbi.nlm.nih.gov/pubmed/11113214>. PMID:
- 42 Fahn S, Elton RL & Members of the Udc (1987) Unified Parkinson's disease rating scale: in *Recent developments in Parkinson's disease* (eds S. Fahn, C. D. Marsen, M. Goldstein, & D. Calne) 433 (Macmillan).
- 43 Folstein MF, Folstein SE & McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr. Res* **12**, 189-198. <http://www.ncbi.nlm.nih.gov/pubmed/1202204>. PMID:
- 44 Creswell JW & Creswell JD (2018) *Research Design: Qualitative, Quantitative, and Mixed Methods Approaches (Fifth Edition)*. 275 (Sage Publications).
- 45 Fetzters MD, Curry LA & Creswell JW (2013) Achieving integration in mixed methods designs-principles and practices. *Health Serv Res* **48**, 2134-2156, doi:10.1111/1475-6773.12117. <https://www.ncbi.nlm.nih.gov/pubmed/24279835>. PMID: PMC4097839
- 46 Guba EG & Lincoln YS (1981) *Effective evaluation: Improving the usefulness of evaluation results through responsive and naturalistic approaches*. (Jossey-Bass).
- 47 Kluger BM, Dolhun R, Sumrall M, Hall K & Okun MS (2021) Palliative Care and Parkinson's Disease: Time to Move Beyond Cancer. *Mov Disord* **36**, 1325-1329, doi:10.1002/mds.28556. <https://www.ncbi.nlm.nih.gov/pubmed/33786871>. PMID: PMC8217287
- 48 Senderovich H & Jimenez Lopez B (2021) Integration of palliative care in Parkinson's disease management. *Curr Med Res Opin*, 1-15, doi:10.1080/03007995.2021.1954895. <https://www.ncbi.nlm.nih.gov/pubmed/34254548>. PMID:
- 49 Creswell JW, Klassen AC, Plano Clark VL & Smith KC (2011) Best Practices for Mixed Methods Research in the Health Sciences. (Office of Behavioral and Social Sciences Research (OBSSR), Bethesda MD USA).
- 50 Anonymous (2015) *PCORI Methodology Standards*, <<https://www.pcori.org/research-results/about-our-research/research-methodology/pcori-methodology-standards#QualitativeMethods>>.

- 51 Prizer LP, Gay JL, Wilson MG, Emerson KG, Glass AP, Miyasaki JM & Perkins MM (2020) A Mixed-Methods Approach to Understanding the Palliative Needs of Parkinson's Patients. *J Appl Gerontol* **39**, 834-845, doi:10.1177/0733464818776794. <https://www.ncbi.nlm.nih.gov/pubmed/29788783>. PMID:
- 52 Sieber BA, Landis S, Koroshetz W, Bateman R, Siderowf A, Galpern WR, Dunlop J, Finkbeiner S, Sutherland M, Wang H, Lee VM, Orr HT, Gwinn K, Ludwig K, Taylor A, Torborg C, Montine TJ & Parkinson's Disease : Advancing Research ILCOC (2014) Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference. *Ann Neurol* **76**, 469-472, doi:10.1002/ana.24261. <https://www.ncbi.nlm.nih.gov/pubmed/25164235>. PMID: PMC5736367
- 53 Young D, Popiolek M, Trapa P, Fonseca KR, Brevard J, Gray DL & Kozak R (2020) D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects. *ACS Chem Neurosci* **11**, 560-566, doi:10.1021/acscemneuro.9b00589. <https://www.ncbi.nlm.nih.gov/pubmed/31971364>. PMID:
- 54 Arnsten AF, Girgis RR, Gray DL & Mailman RB (2017) Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia. *Biological psychiatry* **81**, 67-77, doi:10.1016/j.biopsych.2015.12.028. <https://www.ncbi.nlm.nih.gov/pubmed/26946382>. PMID: PMC4949134
- 55 Sierra M, Carnicella S, Strafella AP, Bichon A, Lhomme E, Castrioto A, Chabardes S, Thobois S & Krack P (2015) Apathy and Impulse Control Disorders: Yin & Yang of Dopamine Dependent Behaviors. *Journal of Parkinson's disease* **5**, 625-636, doi:10.3233/JPD-150535. <https://www.ncbi.nlm.nih.gov/pubmed/25870025>. PMID:
- 56 Trang I, Katz M, Galifianakis N, Fairclough D, Sillau SH, Miyasaki J & Kluger BM (2020) Predictors of general and health-related quality of life in Parkinson's disease and related disorders including caregiver perspectives. *Parkinsonism Relat Disord* **77**, 5-10, doi:10.1016/j.parkreldis.2020.05.036. <https://www.ncbi.nlm.nih.gov/pubmed/32563809>. PMID:
- 57 O'Cathain A (2018) *A practical guide to using qualitative research with randomized clinical trials*. First edn, (Oxford University Press).
- 58 Van Scoy LJ, Green MJ, Creswell JD, Thiede T, Wiegand D, La IS, Lipnick D, Johnson R, Dimmock AE, Foy A, Lehman E, Chinchilli VM & Levi BH (2020) Generating a New Outcome Variable Using Mixed Methods in a Randomized Controlled Trial: The Caregiver Study—An Advance Care Planning Investigation. *Journal of Mixed Methods Research* **1558689820970686**, 20, doi:10.1177/1558689820970686. PMID:
- 59 Wang P, Felsing DE, Chen H, Raval SR, Allen JA & Zhou J (2019) Synthesis and Pharmacological Evaluation of Noncatechol G Protein Biased and Unbiased Dopamine D1 Receptor Agonists. *ACS Med Chem Lett* **10**, 792-799, doi:10.1021/acsmchemlett.9b00050. <https://www.ncbi.nlm.nih.gov/pubmed/31098001>. PMID: PMC6511950
- 60 Davoren JE, Nason D, Coe J, Dlugolenski K, Helal C, Harris AR, LaChapelle E, Liang S, Liu Y, O'Connor R, Orozco CC, Rai BK, Salafia M, Samas B, Xu WJ, Kozak R & Gray D (2018) Discovery and Lead Optimization of Atropisomer D1 Agonists with Reduced Desensitization. *J Med Chem* **61**, 11384-11397, doi:10.1021/acs.jmedchem.8b01622. <Go to ISI>://WOS:000454751100029. PMID:
- 61 Lewis MM, Huang X, Nichols DE & Mailman RB (2006) D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease. *CNS Neurol Disord Drug Targets* **5**, 345-353. <http://www.ncbi.nlm.nih.gov/pubmed/16787233>. PMID:

- 62 Mailman RB (2007) GPCR functional selectivity has therapeutic impact. *Trends Pharmacol Sci* **28**, 390-396, doi:10.1016/j.tips.2007.06.002. <https://www.ncbi.nlm.nih.gov/pubmed/17629962>. PMID: PMC2958218
- 63 Mailman RB, Nichols DE, Lewis MM, Blake BL & Lawler CP (1998) Functional Effects of Novel Dopamine Ligands: Dihydropyridine and Parkinson's Disease as a First Step: in *Dopamine Receptor Subtypes: From Basic Science to Clinical Application Biomedical and Health Research, Vol. 19* (eds P. Jenner & R. Demirdemir) 64-83 (IOS Stockton Press).
- 64 Guetterman TC, Fetters MD & Creswell JW (2015) Integrating Quantitative and Qualitative Results in Health Science Mixed Methods Research Through Joint Displays. *Ann Fam Med* **13**, 554-561, doi:10.1370/afm.1865. <https://www.ncbi.nlm.nih.gov/pubmed/26553895>. PMID: PMC4639381

## FIGURE AND TABLES

Figure 1. Evaluation of quantitative GCI data for four of five subjects.



**Table 1. Convergent mixed methods study design: Constructs and Measures**

Construct	QUAN measure	QUAL measure (Caregiver Interviews)
Motor	MDS-UPDRS-III-motor subscale	Tell me about [patient]’s normal level of <i>[alertness, cognition, facial expression, movement or rigidity, sleep]</i> . How has [patient]’s <i>[alertness, cognition, facial expression, movement or rigidity, sleep]</i> been over the past two days? Tell me about that. <b>PROMPTS (if needed):</b> Can you give some examples of things that you have noticed? How is [patient]’s level of <i>[alertness, cognition, facial expression, movement or rigidity, sleep]</i> different compared to a week ago? How, if at all, has this changed since the infusion started? When did you notice these changes? Have you noticed these kinds of changes before? Tell me more about that.
Alertness	Glasgow Coma scale (GCS) Stanford Sleepiness Scale (SSS)	
Cognition	Severe Impairment Battery (SIB) Frontal Assessment Battery (FAB)	
Sleep	Sleep efficiency	
Overall	Clinician Global Clinical Impression of Change (GCI-C) modified for late-stage stage PD patients Caregiver Global Clinical Impression of Change (GCI-C) questionnaire	

[/ ] includes domain specific words. Abbreviations: QUAN-quantitative, QUAL-qualitative, MDS-UPDRS-III-Movement Disorders Society Unified Parkinson’s Disease Rating Scale motor exam.

**Table 2: Summary of quantitative data.**

<b>Motor function</b>								
	<b>UPDRS-III (+score better)</b>		<b>Clinician</b>		<b>Caregiver</b>			
	<b>Levodopa</b>	<b>PF-2562</b>	<b>levodopa</b>	<b>PF-2562</b>	<b>levodopa</b>	<b>PF-2562</b>		
<b>1</b>	-2	16	2	1	0.2	0.6		
<b>3</b>	4	3	1	3	-0.3	1.7		
<b>4</b>	1	-2	0	2	-0.2	1		
<b>7</b>	-1	-2	0	0	-0.4	0.4		
<b>8</b>	-14	-24	2	4	2.2	0.4		
<b>Alertness</b>								
	<b>GCS (+ score better)</b>		<b>SSS (- score better)</b>		<b>Clinician</b>		<b>Caregiver</b>	
<b>ID</b>	<b>Levodopa</b>	<b>PF-2562</b>	<b>levodopa</b>	<b>PF-2562</b>	<b>levodopa</b>	<b>PF-2562</b>	<b>levodopa</b>	<b>PF-2562</b>
<b>1</b>	2	-3	-1	1	2	2	2	3
<b>3</b>	0	0	0	0	0	2	0	3
<b>4</b>	1	-1	-1	1	1	3	-1	2
<b>7</b>	0	0	-1	0	0	0	0	1
<b>8</b>	-6	-3	-4	-2	2	0	3	1
<b>Cognitive function</b>								
	<b>SIB (+ score better)</b>		<b>FAB (+ score better)</b>		<b>Clinician</b>		<b>Caregiver</b>	
<b>ID</b>	<b>Levodopa</b>	<b>PF-2562</b>	<b>levodopa</b>	<b>PF-2562</b>	<b>levodopa</b>	<b>PF-2562</b>	<b>levodopa</b>	<b>PF-2562</b>
<b>1</b>	0	0	-3	0	1	1	0	0.7
<b>3</b>	-1	1	1	-3	0	1	0	1.7
<b>4</b>	-1	1	3	-3	-1	3	-0.5	1.5
<b>7</b>	0	0	1	-2	0	0	-0.3	0
<b>8</b>	0	0	-3	0	1	0	1.7	0.2
<b>Sleep</b>								
	<b>SE (+score better)</b>		<b>Clinician</b>		<b>Caregiver</b>			
	<b>Levodopa</b>	<b>PF-2562</b>	<b>levodopa</b>	<b>PF-2562</b>	<b>levodopa</b>	<b>PF-2562</b>		
<b>1</b>	-3.4	-9.4	2	0	1	3		
<b>3</b>	N/A	N/A	0	0	0	2		
<b>4</b>	N/A	N/A	0	0	0	0		
<b>7</b>	0.5	-6	0	0	-1	2		
<b>8</b>	33.5	32.7	2	0	1	0		

**Abbreviations:** FAB: Frontal assessment battery; GCS=Glasgow coma scale; SE: sleep efficiency; SSS=Stanford sleepiness scale; SIB: Severe impairment battery; UPDRS-III: Movement Disorders Society Unified Parkinson's Disease Rating Scale, subscore III.

Quantitative data in each domain first represent standard clinical instruments for measuring that domain. The scores represent the difference between the last measure on Day 3 (2 h after second dose of study medication) and the first measure on Day 2 (prior to administration of any study medication). For the GCS (best score=15), SIB (best score=133), and FAB (best score=18), higher scores represent better performance, whereas for the SSS (best score=1) and MDS-UPDRS-III (best score=0) higher scores represent worse performance.

The clinical global impression of change (GCI-C) in each domain was assessed at the end of Day 3 by the movement disorder specialist (clinician) or caregiver. The caregiver score is the average of several checklist items related to that domain: Alertness: 1 item; Cognition: 4 items; Motor: 5 items; Sleep: 1 item. The following scale was used: +3-Marked improvement, +2-Moderate improvement, +1-Minimal improvement, 0-No change, -1-Minimal worsening, 2-Moderate worsening, -3-Marked worsening.

Shading for the standard clinical instruments indicate whether the scores improved (light gray) or worsened (dark gray) for levodopa and PF-2562. For the clinical and caregiver GCI-C scores, the shading indicates which treatment was favored (light gray favored, dark gray not favored). No shading represents no change in scores (standard clinical instruments) or equivocal scores (GCI-C ratings).



**Table 3. Qualitative data transformation and quotations (PF-2562 in grey cells)**

		<b>Data Transformation</b>	<b>Additional Qualitative Insights</b>	<b>Quotes</b>
<b>Subject 1</b>	<b>Levodopa</b>	Improved cognitive engagement (alertness/cognition) Improved motor and strength Either mildly improved or no $\Delta$ swallowing	CG notes that patient was more alert and social than at home, but also attributes this to a change in environment and rigidity of schedule, increased stimulation from staff. Patient looking around room, calling staff by name and had improved facial expressions and movements. More closed mouth ('peaceful') breathing. Unclear if changes in sleep or napping	<i>"...he is certainly more alert and aware, however it's comparable to when he has a really good day at home"</i>  <i>"...the high point was..., where he picked the hat up and... trying very hard to put it on...he reached out and took hold of [research assistant's] hand,...looked at him,...attended to him, and... asked [him] for the hat...that was probably the most...purposeful activity we have seen in a while."</i>
	<b>PF-2562</b>	Improved cognitive engagement (alertness/cognition) Improved motor and strength Either mildly improved or unchanged swallowing	Has had some moments of alertness at home, but not nearly as long as here. Try to speak, had improved alertness and cognition, better movements and strength when pushing things away. Jerking movements of arms. Less drooling. Unclear if changes in sleep or napping	<i>"...I was enjoying the alertness and interaction during, and it was so long...really good to have him that alert" "... he definitely engaged [more]...if you spoke to him, he would turn back... those moments are shorter at home."</i>  <i>"He could set his foot up so his knee was up high,... cross his legs, and I have seen him at home struggle to cross his legs... there are a couple of very purposeful things that actually worked both yesterday... &amp; this afternoon."</i>
<b>Subject 3</b>	<b>Levodopa</b>	No $\Delta$ cognitive engagement (alertness/cognition), movement Wax & wane in facial expression No $\Delta$ swallowing or breathing	Overall, no major changes Needs assistance with balance, standing, walking Worse toe tapping	<i>"I would say [alertness has been] the same as at home."</i>  <i>"We went around last evening and he froze up a good bit...the same as at home...instead of [MD] just holding on to him a little..., he did okay, but it's not like last [PF] week... just the same as home, he's not real steady. Somebody definitely has to hold on to him or he'd fall."</i>
	<b>PF-2562</b>	Improved cognitive engagement (alertness/cognition) Improved facial expression Improved movement and muscle weakness No $\Delta$ swallowing or breathing	Much improved walking compared to home, able to do side steps, he was 'walking right along' [with MD] Improved mood and alertness; able to pay attention and follow along with a TV show Smiling for first time in 2 years Less messy eating, eating well with a spoon	<i>"I see his personality today. like before he got Parkinson's...he was just a lot of fun and [came] up with wise cracks and stuff and he was just like his old self today..."</i>  <i>"We couldn't believe how good he was walking here. Even made the side steps to come back and get on his chair again, so that was definitely an improvement from home."</i>

Subject 4	Levodop	No $\Delta$ in facial expression Mild/slight improved cognitive engagement (alertness-/cognition), movement	Difficult to assess changes because she commonly has peaks and valleys Wax and wane at baseline. Somewhat improved focus on walking	<i>"...it's not terribly far off from home...I would say that on average she has been as good if not just a hair better here."</i>
	PF-2562	No $\Delta$ in cognitive engagement (alertness/cognition) or waxing and waning Worse facial expression	Appears less erratic, less waxing & waning. More consistent focus, less distraction on her tasks Very deep sleep, nearly unresponsive, urinated in bed	<i>"I would say slightly better here...but even here, she is off crashing into things." "She is more consistently off- there are still ups and downs but it's less distant between the peaks and valleys."</i>
	Levodopa	Worse cognitive engagement (alertness/cognition) Worse movements No $\Delta$ in balance No $\Delta$ in bladder	Overall, more lethargic & worse cognition, although some improved alertness on day 2 that CG attributes to posture in chair and new setting, became more lethargic once acclimated, hard to arouse Twitching and jumpy during sleep	<i>"We could not arouse him....he was a little bit interactive with the ice water and then [research assistant] finally just got real in his face and started talking to him in that man voice... that was the first time he opened his eyes. It was taking him longer sometimes to come up with what he wanted to say." "He was twitching and jumping...I have never seen that."</i>
Subject 7	PF-2562	Improved cognitive engagement:(alertness/cognition) and facial expression. Worse movements and strength Improved balance	Better mood & interaction, felt 'energized' and 'optimistic' although notes some grogginess on Day 2. Interactions and stimulation have been helpful. Slower movements and muscle weakness More frequent urination, sensed need to go	<i>"He said 'I feel energized, I feel excited about today. I feel like doing things' a couple of times." I think the movements are a little bit slower than when he is on his typical [meds]...the pace has been pretty slow but...he hasn't been losing his balance. He has been...much better today" [with regards to balance].</i>

<b>Subject 8</b>	<b>levodopa</b>	Improved cognitive engagement (alertness/cognition)	Dramatic response in alertness, responsiveness, memory & communication	<p><i>“Today it seemed to change completely. He made conversation, he greeted people...he responded to questions and could bring up some memories and verbalize them... it’s a big change today.”</i></p> <p><i>“That’s something a little new [twitching], it’s not that he has never done it at home... he jerks, but, yeah, he has been twitching and jerking quite a bit here...I wouldn’t say it’s increased necessarily. Today right now we are seeing quite a bit of it, but last week was more.”</i></p>
		Improved facial expressions	Shook someone’s hand to greet them, able to move more	
	Improved movements	Became more tired & lethargic as day wore on		
	Unclear $\Delta$ twitching			
	<b>PF-2562</b>	No $\Delta$ or Improved cognitive engagement (alertness/cognition)	Worse twitching of arms and legs No major changes noted by CG	<p><i>“[He] has been very stimulated... so many people coming and going and all the activity, a lot more than he gets at home...but I don’t think it is any different than what he would have responded to before.”</i></p> <p><i>“I don’t see a big change in [movement or muscle tone]....he’s been very stiff, very rigid, um, but I think this morning he was a little looser...When he was examined, things seem to be better, but he’s back to being very stiff and rigid.”</i> “Um...he was very twitchy today which was something new.”</p>
		No $\Delta$ facial expression	CG notes increased stimulation from environment	
		No $\Delta$ swallowing		
		Waxing and waning movements and rigidity		

Abbreviations: CG: Caregiver

**Table 4. Mixed methods integrated joint display merging quantitative and qualitative data and conclusions.**

Domain of interest	Quantitative		Qualitative		Data Integration	Conclusion
	Rater	Clinician	Caregiver			
	Scale	GCI	GCI	Interview		
Motor	Equivocal	Equivocal	Favor PF-2562 in first 4 subjects	Favor PF-2562 in first 4 subjects	PF-2562 was superior to levodopa according to caregiver data.	<ul style="list-style-type: none"> <li>Standard and clinician-based evaluations are equivocal.</li> </ul>
Alertness	Equivocal	Equivocal	Favor PF-2562 in first 4 subjects	Favor PF-2562 in first 4 subjects	PF-2562 was superior to levodopa according to caregiver data.	<ul style="list-style-type: none"> <li>Caregiver data converges in 4/5 patients, favoring PF-2562.</li> </ul>
Cognition	Equivocal	Equivocal	Favor PF-2562 in first 4 subjects	Favor PF-2562 in first 4 subjects	PF-2562 was superior to levodopa according to caregiver data.	<ul style="list-style-type: none"> <li>Key efficacy domains are motor, alertness, and engagement/cognition.</li> </ul>
Sleep	Incomplete	Equivocal	Equivocal	Equivocal	Sleep data is incomplete and equivocal between the two drugs.	<ul style="list-style-type: none"> <li>Last subject has unique features and responses, shall analyze and discuss separately.</li> </ul>

## SUPPLEMENTAL INFORMATION

### *Supplemental Text A: Details of Quantitative Analysis*

#### Standard scales

As noted in the text, the standardized validated scales assessing alertness, cognition, motor function, and sleep did not detect a significant pattern of differences between levodopa and PF-2562. The clinician ratings were also equivocal (Table 2). For alertness, levodopa improved GCS scores in two participants (1 and 4), worsened them in one (8), and had no effect in two (3 and 7), whereas PF-2562 worsened scores in three participants (1, 4, and 8) and had no effect in two (3 and 7). Levodopa improved SSS scores in 4 participants (1, 4, 7, and 8) and had no effect in one (3), whereas PF-2562 improved SSS score in one participant (8), worsened two (1 and 4), and had no effect in two (3 and 7). For cognition, levodopa worsened SIB scores for two participants (3 and 4) and had no effect in three (1, 7, and 8), whereas PF-2562 improved SIB scores in two participants (3 and 4) and had no effect in three (1, 7 and 8). Levodopa improved FAB scores in three participants (3, 4, and 7) and worsened them in two (1 and 8), whereas PF-2562 worsened FAB scores in three participants (3, 4, and 7) and had no effect in two (1 and 8). For motor function, levodopa improved MDS-UPDRS-III scores in two participants (3 and 4) and worsened them in three (1, 7, and 8), whereas PF-2562 improved MDS-UPDRS-III scores in two participants (1 and 3) and worsened them in three (4, 7, and 8). For sleep efficiency, levodopa improved scores in two participants (7 and 8) and worsened them in one (1), whereas PF-2562 improved sleep efficiency in one participant (7) and worsened it in two (1 and 8).

#### Clinician CGI Ratings

For alertness, clinician GCI-C scores favored levodopa in one participant (8), PF-2562 in two (3 and 4), and were equivocal in two (1 and 7; Table 2). Clinician GCI-C scores for cognition favored levodopa in one participant (8), PF-2562 in two (3 and 4), and were equivocal in two (1 and 7). For motor function, GCI-C scores favored levodopa in one participant (1), PF-2562 in three (3, 4 and 8) and were equivocal in one (7). Clinician GCI-C scores for sleep efficiency favored levodopa in two participants (1 and 8) and were equivocal in three (3, 4, and 7).


#### Caregiver CGI Ratings

For alertness, caregiver GCI-C scores favored levodopa in one participant (8) and PF-2562 in four (1, 3, 4, and 7; Table 2). Caregiver GCI-C scores for cognition favored levodopa in one participant (8) and PF-2562 in four (1, 3, 4, and 7). For motor function, caregiver GCI-C scores favored levodopa in two participants (1 and 8) and PF-2562 in three (3, 4, and 7). Caregiver GCI-C scores for sleep efficiency favored levodopa in one participant (8) and PF-2562 in four (1, 3, 4, and 7).

### *Supplemental Text B: Details of Qualitative Analysis*

As noted in the text, a conventional content analysis approach that included data transformation was used to evaluate the data.<sup>44</sup> Published guidelines for methodological rigor of qualitative analysis were followed to ensure attention to the truth-value, applicability, consistency, and neutrality of the findings<sup>44,46</sup>. Three independent, blinded analysts used qualitative software (NVivo Ver. 11.0, QSR International, Melbourne Australia) to code and analyze the data. **First**, a preliminary codebook was developed inductively based on the common concepts that emerged from the data. The codebook followed closely the structured interview domains yet also included unexpected categories and concepts that were included in the final codebook. **Second**, the preliminary codebook was applied to an additional three transcripts and minor codebook adjustments were made to fit the additional data. Some domains were collapsed as appropriate based on the data. Data saturation (the point at which no new codes emerge) was achieved after reviewing 6 of 12 transcripts (one per participant per treatment week) and the final codebook contained codes for each of the key efficacy domains as well as caregiver observations from the home and study environments. **Third**, the finalized codebook then was used to recode the entire dataset by two coders. Codes were adjudicated by a third analyst to ensure inter-rater reliability. Discrepancies were reconciled via group discussions. **Finally**, analysts used data transformation to convert the qualitative data into categories (i.e., improved, worsened, remained unchanged) for each domain based on the codebook. Any differences in coding was reconciled by group discussion<sup>64</sup>.

**Supplemental Figure A. Study schematic.**



*\*Treatment: Dosing: 9 am, 1 pm, 5 pm, optional 9 pm, Levodopa: tid-qid, or PF-06412562: bid + placebo  
Outcome efficacy evaluations are based on the last evaluation and caregiver interview of Day 3.*

*This is*

*a schematic of the overall design of the study (modified from <sup>32</sup>). Subjects were randomized to receive PF-2562 followed by levodopa (Sequence A, top) or levodopa followed by PF-2562 (Sequence B). PF-2562 (5 mg) or placebo tablets were provided by Pfizer. Sinemet (carbidopa/levodopa, 25/100 mg) tablets were encapsulated to preserve study blind. The bottom part of the schematic shows the events that occurred on each day. Levodopa dose was based on home dosage and regimen. Some subjects received a fourth dose of levodopa if that was required according to their pretrial dosing regimen. Outcome efficacy data are based on the last evaluation and caregiver interview of Day 3.*

**Supplemental Table A. Direct or indirect dopamine receptor agonists that have been approved or in PD clinical trials**

<b>Drug Class</b>	<b>Target(s)</b>	<b>Current Status</b>	<b>Clinical Effects</b>	<b>Side Effects</b>
<b>Levodopa (indirect dopamine agonist)</b> [levodopa/carbidopa based-combinations or formulations]	Results in dopamine that targets all dopamine receptors At higher doses, may affect “off-target” receptors due to “off-site” DA	Standard-of-care for Parkinson’s disease since 1967 (formulations include <i>Sinemet, Parcopa, Duodopa, Rytary; Stalevo; Bendopa, Inbrija</i> )	Very effective in early and mid-stage disease	More side effects with disease progression (dyskinesias, on-off; hypotension; drowsiness and hallucinations in later stages)
<b>“D<sub>1</sub> agonists” (D<sub>1</sub>-D<sub>5</sub> non-selective)</b>	Dihydropyridine (full agonist)	Non-human primates; Phase Ib	Very effective in severely PD non-human primates	Severe hypotension in humans; short-acting; injectable only
	ABT-431 (full agonist)	two published Phase II trials	Very effective in mid-stage PD	Hypotension; nausea; injectable only
	PF-06412562 (PF-2562)	Phase IIa	Effective in mid-stage PD	Hypotension; nausea
	tavapadon (PF-06649751)	Phase III	Effective in mid-stage PD	Hypotension; nausea
<b>“Dopamine agonists” (selective D<sub>2</sub>/D<sub>3</sub>)</b>	cabergoline (Dostinex)	(withdrawn, valvulopathy)	Moderate efficacy (does not match levodopa); used for earlier stage PD and as adjuvant	Hypotension; obsessive and compulsive disorders; Drowsiness; hallucinations
	pramipexole (Mirapex)	Approved drug		
	ropinirole (Requip)	Approved drug		
<b>“Dopamine agonists” (selective D<sub>2</sub>/D<sub>3</sub> with some D<sub>1</sub> affinity)</b>	bromocriptine (Parlodel)	Approved drug; D <sub>1</sub> antagonist	Moderate efficacy	Hypotension; obsessive and compulsive disorders; Drowsiness, hallucinations
	pergolide (Permax)	Withdrawn (valvulopathy); D <sub>1</sub> partial agonist	More effective than bromocriptine	
	rotigotine (Neupro)	Approved drug (patch)	Patch only	
	apomorphine (Apokyn)	Approved drug (injection or sublingual)	Short-acting; effective for rescue	



**Supplemental Table B. Demographic, clinical history, and baseline data for the randomized participants**

<b>ID</b>	<b>Demographic, key medical &amp; surgery milestones</b>	<b>Current medication</b>	<b>Disease stages and severity</b>	<b>Caregiver perspective Key narrative/phrases from qualitative interviews</b>
<b>1</b>	M, PD at 36-40y; pallidotomy at 46-50 y; wheelchair use at 61-65 y; PEG at 61-65 y	DA drugs: Parcopa; Non-DA drugs: rivastigmine transdermal	HY stage: 5; MD-GCI-S: 6 CG-GCI-S: 96	Periods of intermittent wakefulness between mid-am to later-pm, less alert after levodopa. Requires two people to help him out of bed, stiff in am. Incontinent at baseline.
<b>3</b>	M, PD at 55-60 y; STN-DBS at 66-70 y; walker & wheelchair use at 76-80 y	DA drugs: Sinemet R and CR; Non-DA drugs: Vitamin B12	HY Stage: 4-5; MD-GCI-S: 4 CG-GCI-S: 37	Trouble with concentration, often not remembering things. Discomfort with social interactions, doesn't smile, appears sad. Sleepy after drugs. Hard time getting up, freezing. Uses a chair lift. Often days & nights 'mixed up.'
<b>4</b>	F, PD at 56-60 y, STN-DBS at 61-65 y, Walker use at 66-70 y, Wheelchair use at 66-70 y	DA drugs: Sinemet R and CR, Rytary, selegiline, pramipexole; Non-DA Drugs: dextansoprazole, melatonin, midodrine, donepezil, memantine, clozapine, rimanta- dine, methylphenidate, venlafaxine fludrocortisdone	HY Stage: 4-5; MD-GCI-S: 5 CG-GCI-S: 52	Confusion, peaks and valleys, emotional, a blank facial expression. Often urgency and incontinence and constipation. Sleeps deeply >14 h/day. Has a lot of dreaming and vocalization, particularly in second half of the night. Nocturnal movements wax and wane. Some difficulty with swallowing pills.
<b>6</b>	F, PD at 56-60 y; Walker use at 76-80 y; Wheelchair at 76-80	DA drugs: Rytary, Sinemet; Non- DA drugs: gabapentin, donepezil, lorazepam, quetiapine, melatonin, tramadol	HY Stage: 4-5; MD-GCI-S: 4 CG-GCI-S: 10	Some mild short-term memory problems. Naps 3-4 hours per day, frequent awakenings at night with vocalizations. Mild swallowing problems if she eats too quickly.
<b>7</b>	M, PD at 51-55 y; Cane use at 71-75 y; Wheelchair use at 71-75 y	DA drugs: Rytary, rasagiline; Non- DA drugs: donepezil	HY Stage: 4-5; MD-GCI-S: 4 CG-GCI-S: 38	Varying in alertness, doesn't communicate much with facial expressions, shows strong emotions occasionally. Stooped posture with head tilted right. Issues with frozen foot. Yells in sleep, frequent dreams.
<b>8</b>	M, PD dx at 41-45 y; Levodopa was stopped due to severe drossiness at 66-70 y; Bed-bound at 66-70 y	DA drugs: none; Non-DA drugs: none	HY Stage: 5; MD-GCI-S: 6 CG-GCI-S: 64	Sleeps for days at a time, not very cognitive when awake, has difficulty verbalizing. Does not connect with others or TV or music. Does not move, feed, or hold anything. Lacks facial expression. Vocalizes in dreams, occasionally move leg in sleep.

All subjects were aged  $\geq 66$  y at the time of study enrollment. Abbreviations: CGI-S: Clinical global impression of disease severity rated by a movement disorder (MD) specialist or caregiver (CG); DA: Dopaminergic; Dx: Diagnosis; F: Female; HY: Hoehn & Yahr; M: Male; PEG: Percutaneous endoscopic gastrostomy; Sinemet: carbidopa/levodopa; R: regular release; CR: controlled release. \*\* MD-CGI-S was rated by clinician at baseline on Day 1, from 1 to 7, 1=normal to 7=extremely ill. CG-GCI-S was a 17 item scale rated by the caregiver on Day 1 with each item rated from 1=normal to 7=extremely ill. Maximal score was 102.

Parcopa, Sinemet, and Rytary are proprietary formulations of levodopa.

These data originally were reported in <sup>32</sup> Only epochs used here per medRxiv rules



## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	3
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale	4-5
	2b	Specific objectives or hypotheses	4-5
<b>Methods</b>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	5-6
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	NA
Participants	4a	Eligibility criteria for participants	5
	4b	Settings and locations where the data were collected	5
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	5-6
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	6-7
	6b	Any changes to trial outcomes after the trial commenced, with reasons	NA
Sample size	7a	How sample size was determined	5
	7b	When applicable, explanation of any interim analyses and stopping guidelines	NA
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	5-6
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	5-6
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	5-6
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	5-6
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	5
	11b	If relevant, description of the similarity of interventions	NA
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	7-8

	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	NA
<b>Results</b>			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	8
Recruitment	13b	For each group, losses and exclusions after randomisation, together with reasons	8
	14a	Dates defining the periods of recruitment and follow-up	5-6
	14b	Why the trial ended or was stopped	NA
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Supp Table B
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	8
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	NA
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	N/A
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	9-10
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	8
<b>Discussion</b>			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	13
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	11-13
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	11-13
<b>Other information</b>			
Registration	23	Registration number and name of trial registry	3
Protocol	24	Where the full trial protocol can be accessed, if available	5
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	1-2

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).



# CONSORT

TRANSPARENT REPORTING of TRIALS

## CONSORT 2010 Flow Diagram

*Blinded cross-over design*  
*Left column PF-2562; right column-levodopa*

